SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-254004
Filing Date
2020-09-25
Accepted
2020-09-25 09:22:01
Documents
12
Period of Report
2020-09-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d77264d8k.htm   iXBRL 8-K 29285
2 EX-10.1 d77264dex101.htm EX-10.1 80548
3 EX-10.2 d77264dex102.htm EX-10.2 38624
  Complete submission text file 0001193125-20-254004.txt   303169

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kpti-20200923.xsd EX-101.SCH 3075
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20200923_lab.xml EX-101.LAB 18138
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20200923_pre.xml EX-101.PRE 11411
7 EXTRACTED XBRL INSTANCE DOCUMENT d77264d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 201197050
SIC: 2834 Pharmaceutical Preparations